ABT-288

DRUG2 trials

Sponsors

AbbVie, AbbVie (prior sponsor, Abbott)

Conditions

Alzheimer's DiseaseSchizophrenia

Phase 1

A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia

CompletedNCT00888693

AbbVieSchizophrenia

Start: 2008-11-30Updated: 2017-11-21

Phase 2

Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease

CompletedNCT01018875

AbbVie (prior sponsor, Abbott)Alzheimer's Disease

Start: 2009-12-31End: 2011-02-28Updated: 2018-06-06